- In October 2024, LEO Pharma released the financial highlights from first nine months of 2024, The company delivered revenue growth of 11% in constant exchange rates (CER). The dermatology portfolio saw revenue growth of 13%. It also included several key events around the globe such as the European Commission’s approval of Anzupgo (delgocitinib) cream for adults with moderate to severe chronic hand eczema (CHE)
- In October 2024, Organon announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. It included acquisition of VTAMA (tapinarof) cream, 1%, which is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque psoriasis
- In August 2024, DermBiont, announced positive initial data from its ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC). The results showed that lesions which were treated with SM-020 1% gel BID (twice daily) for 28 days, with the primary endpoint based on percent change from baseline in greatest tumor diameter at week 6, showed a prompt (within days of starting treatment) and robust clinical response to the application of SM-020 1% gel, clearly demonstrating the disease modifying potential of SM-020
- In May 2024, Johnson & Johnson announced that it had reached a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology firm specializing in bispecific antibodies for immune-related diseases, for $850 million in cash, with the potential for additional milestone payments. Proteologix’s pipeline includes PX128, a bispecific antibody targeting IL-13 and TSLP, which is poised to enter Phase 1 development for the treatment of moderate to severe atopic dermatitis (AD) and moderate to severe asthma
- In March 2024, Amgen announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in pa tients for up to one year
